Clinical Trial Update: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing the novel insulin analog insulin Efsitora Alfa (LY3209590) with insulin degludec in adults with type 2 diabetes who are initiating bas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Degludec (degludec)
• Insulin Efsitora Alfa (LY3209590)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes, Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2025-05-16